JP2007515433A - Cyp26aおよびcyp26bの選択的阻害剤を使用するレチノイド反応性障害の処置方法 - Google Patents

Cyp26aおよびcyp26bの選択的阻害剤を使用するレチノイド反応性障害の処置方法 Download PDF

Info

Publication number
JP2007515433A
JP2007515433A JP2006545811A JP2006545811A JP2007515433A JP 2007515433 A JP2007515433 A JP 2007515433A JP 2006545811 A JP2006545811 A JP 2006545811A JP 2006545811 A JP2006545811 A JP 2006545811A JP 2007515433 A JP2007515433 A JP 2007515433A
Authority
JP
Japan
Prior art keywords
disorders
mmol
disorder
selective
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515433A5 (cg-RX-API-DMAC7.html
Inventor
バスデバン,ジャヤスリー
ヤン,ロン
ワン,リーミン
リウ,シアオシア
ツァン,クウォック,イン
リー,リン
タケウチ,ジャネット,エイ.
ブ,トン
ビアード,リチャード,エル.
バート,スミタ
チャンドララトナ,ロシャンタ,エイ.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2007515433A publication Critical patent/JP2007515433A/ja
Publication of JP2007515433A5 publication Critical patent/JP2007515433A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006545811A 2003-12-17 2004-12-13 Cyp26aおよびcyp26bの選択的阻害剤を使用するレチノイド反応性障害の処置方法 Pending JP2007515433A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53060103P 2003-12-17 2003-12-17
PCT/US2004/041889 WO2005058301A1 (en) 2003-12-17 2004-12-13 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b

Publications (2)

Publication Number Publication Date
JP2007515433A true JP2007515433A (ja) 2007-06-14
JP2007515433A5 JP2007515433A5 (cg-RX-API-DMAC7.html) 2008-02-07

Family

ID=34700149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545811A Pending JP2007515433A (ja) 2003-12-17 2004-12-13 Cyp26aおよびcyp26bの選択的阻害剤を使用するレチノイド反応性障害の処置方法

Country Status (5)

Country Link
US (1) US7468391B2 (cg-RX-API-DMAC7.html)
EP (1) EP1696899A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007515433A (cg-RX-API-DMAC7.html)
CA (1) CA2550010A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005058301A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041482A1 (ja) * 2007-09-28 2009-04-02 Fujifilm Corporation アセチレン化合物
JP2010532355A (ja) * 2007-06-29 2010-10-07 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療するアルキニルフェニル誘導体化合物
WO2020171146A1 (ja) * 2019-02-20 2020-08-27 第一三共株式会社 アゾール誘導体

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
JP2009500297A (ja) * 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
KR101057546B1 (ko) * 2007-06-05 2011-08-17 주식회사 엘지화학 광학 이방성 화합물 및 이를 포함하는 수지 조성물
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
BRPI0908033A2 (pt) 2008-02-21 2015-08-04 Centocor Ortho Biotech Inc Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
CN108486040A (zh) * 2008-06-30 2018-09-04 詹森生物科技公司 多能干细胞的分化
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
EP2346988B1 (en) * 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
JP2012507289A (ja) 2008-10-31 2012-03-29 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
CA2744227C (en) * 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
MX2011005288A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Celulas madre pluripotentes en microportadores.
EP2456858B1 (en) * 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2456862A4 (en) 2009-07-20 2013-02-27 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
RU2540016C2 (ru) 2009-07-20 2015-01-27 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека
US20120190716A1 (en) * 2009-08-05 2012-07-26 Oehlen Lambertus J W M Methods and uses of cytochrome p450 inhibitors
RU2664864C1 (ru) 2009-12-23 2018-08-23 Янссен Байотек, Инк. Способы увеличения экспрессии ngn3 и nkx6.1 в эндокринных клетках поджелудочной железы
DK2516625T3 (da) 2009-12-23 2024-09-09 Janssen Biotech Inc Differentiering af humane embryonale stamceller
AU2011223900A1 (en) * 2010-03-01 2012-09-13 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
JP2014527083A (ja) 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ, ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ, アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
MX354775B (es) 2012-03-07 2018-03-20 Janssen Biotech Inc Medios definidos para la expansion y el mantenimiento de celulas madre pluripotentes.
CN104334719B (zh) 2012-06-08 2018-02-13 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
KR102084561B1 (ko) 2012-12-31 2020-03-04 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 공기-액체 계면에서의 인간 배아 줄기세포의 배양
DK2938722T3 (da) 2012-12-31 2022-02-14 Janssen Biotech Inc Suspension og klyngedannelse af humane pluripotente celler til differentiering til endokrine pankreasceller
MX2015008578A (es) 2012-12-31 2015-09-07 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
SG11201609473XA (en) 2014-05-16 2016-12-29 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
WO2016055800A2 (en) * 2014-10-10 2016-04-14 High Force Research Limited Fluorescent synthetic retinoids
CN105481723B (zh) * 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
CN107176945B (zh) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用
WO2017180361A1 (en) 2016-04-14 2017-10-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
WO2019113693A1 (en) * 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044443A2 (en) * 1999-12-16 2001-06-21 Cytochroma Inc. Cytochrome p450rai-2 and related proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599967A (en) 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
WO2002048334A2 (en) 2000-12-15 2002-06-20 Cytochroma Inc. P450rai-2 (p450 cytochrome 26b), encoding nucleic acid molecules and methods and uses thereof
US6303785B1 (en) 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6252090B1 (en) * 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) * 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) * 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
GB0204735D0 (en) * 2002-02-28 2002-04-17 Inpharmatica Ltd Protein
CN1819996B (zh) 2003-07-10 2010-10-27 Osi制药公司 作为细胞色素p450抑制剂的亚萘基衍生物
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044443A2 (en) * 1999-12-16 2001-06-21 Cytochroma Inc. Cytochrome p450rai-2 and related proteins

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532355A (ja) * 2007-06-29 2010-10-07 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療するアルキニルフェニル誘導体化合物
US8299307B2 (en) 2007-06-29 2012-10-30 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US8389771B2 (en) 2007-06-29 2013-03-05 Acucela, Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US8492589B2 (en) 2007-06-29 2013-07-23 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US8766007B2 (en) 2007-06-29 2014-07-01 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US8895782B2 (en) 2007-06-29 2014-11-25 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US9115056B2 (en) 2007-06-29 2015-08-25 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US9464033B2 (en) 2007-06-29 2016-10-11 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2009041482A1 (ja) * 2007-09-28 2009-04-02 Fujifilm Corporation アセチレン化合物
WO2020171146A1 (ja) * 2019-02-20 2020-08-27 第一三共株式会社 アゾール誘導体

Also Published As

Publication number Publication date
US7468391B2 (en) 2008-12-23
WO2005058301A1 (en) 2005-06-30
CA2550010A1 (en) 2005-06-30
EP1696899A1 (en) 2006-09-06
US20050187298A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
US7468391B2 (en) Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
JP2007514773A (ja) 選択的シトクロムp450rai−1または選択的シトクロムp450rai−2阻害活性を有する化合物およびそれを得る方法
US6387892B1 (en) Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
JP2001504458A (ja) レチノイド受容体に対し作動剤、拮抗剤または逆作動剤型活性を有するn―アリール置換テトラヒドロキノリンリガンド
JP2003509399A (ja) 製薬学的性質を有する新規なジカルボン酸誘導体
US6291677B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
JP2001515516A (ja) 血管損傷剤としてのコルヒノール誘導体の使用
DE60116642T2 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
AU2001286471A1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6359135B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6303785B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
AU2003213848B2 (en) Substituted chroman derivatives having cytochrome P450RAI inhibitory activity
US7019034B2 (en) Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6387951B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6369261B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) Compounds having activity as inhibitors of cytochrome P450RAI
MXPA06006820A (en) Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US6734193B1 (en) (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
TW201930261A (zh) 光學活性之反式蝦紅素衍生物或其鹽、及含有該等化合物之組合物
SG172277A1 (en) Cyclohexanecarboxamide derivatives useful as inhibitors of cholesteryl ester transfer protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110706